Proprietary products to drive Diaxonhit’s growth in 2016
Diaxonhit is a company developing, producing, and marketing in vitro diagnostic (IVD) tests. Diaxonhit’s expertise in IVD development resides in genomics and proteomics technologies. The company has a dual business model comprised of the distribution of a wide range of IVD tests in France, Belgium and Switzerland through its Ingen subsidiary, and with the development of innovative IVD tests. The company has generated a well-balanced portfolio of proprietary products and licensed IVD tests (Figure 1), and expects to create value through internal growth (proprietary products, increase in revenues, improved margins, etc.), and external growth through company or IVD assets acquisition. This report focuses on Diaxonhit’s current IVD product portfolio, and provides an update on their development. Our target price for Diaxonhit is €1.62/share.
First French company dedicated to life sciences and healthcare company financing, Aurgalys assists private or listed companies during capital increase, provides equity research or valuation services, takes care of investor relations and assists the management for their strategy and business development. Listing Sponsor Alternext (NYSE Euronext). Conseil en Investissement Financier ORIAS - ACIFTE.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.